KR102338079B1 - 젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법 - Google Patents

젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법 Download PDF

Info

Publication number
KR102338079B1
KR102338079B1 KR1020167027303A KR20167027303A KR102338079B1 KR 102338079 B1 KR102338079 B1 KR 102338079B1 KR 1020167027303 A KR1020167027303 A KR 1020167027303A KR 20167027303 A KR20167027303 A KR 20167027303A KR 102338079 B1 KR102338079 B1 KR 102338079B1
Authority
KR
South Korea
Prior art keywords
gemcitabine
bladder
drug
day
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167027303A
Other languages
English (en)
Korean (ko)
Other versions
KR20160124425A (ko
Inventor
데니스 기에싱
희진 이
카렌 다니엘
Original Assignee
타리스 바이오메디컬 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타리스 바이오메디컬 엘엘씨 filed Critical 타리스 바이오메디컬 엘엘씨
Publication of KR20160124425A publication Critical patent/KR20160124425A/ko
Application granted granted Critical
Publication of KR102338079B1 publication Critical patent/KR102338079B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
KR1020167027303A 2014-03-06 2015-03-06 젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법 Active KR102338079B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
US61/949,215 2014-03-06
PCT/US2015/019262 WO2015134911A1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (2)

Publication Number Publication Date
KR20160124425A KR20160124425A (ko) 2016-10-27
KR102338079B1 true KR102338079B1 (ko) 2021-12-09

Family

ID=52697553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027303A Active KR102338079B1 (ko) 2014-03-06 2015-03-06 젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법

Country Status (24)

Country Link
US (3) US20150250717A1 (enExample)
EP (2) EP4124339B1 (enExample)
JP (4) JP6901858B2 (enExample)
KR (1) KR102338079B1 (enExample)
CN (2) CN106102751A (enExample)
AU (4) AU2015226901B2 (enExample)
BR (1) BR112016020381A8 (enExample)
CA (1) CA2939979C (enExample)
DK (2) DK3113782T3 (enExample)
ES (1) ES2930435T3 (enExample)
FI (1) FI4124339T3 (enExample)
HR (2) HRP20221252T1 (enExample)
HU (1) HUE060704T2 (enExample)
IL (2) IL247347B2 (enExample)
LT (2) LT3113782T (enExample)
MX (1) MX2016011333A (enExample)
PL (2) PL4124339T3 (enExample)
PT (2) PT3113782T (enExample)
RS (2) RS67337B1 (enExample)
RU (1) RU2694902C1 (enExample)
SG (2) SG11201607342QA (enExample)
SI (1) SI4124339T1 (enExample)
SM (2) SMT202200449T1 (enExample)
WO (1) WO2015134911A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104812395A (zh) 2012-08-31 2015-07-29 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
CN113413537A (zh) 2013-08-19 2021-09-21 塔里斯生物医药公司 多单元药物递送装置和方法
RS67337B1 (sr) * 2014-03-06 2025-11-28 Taris Biomedical Llc Sistemi za isporuku leka i metode za lečenje karcinoma bešike gemcitabinom
WO2017193098A1 (en) * 2016-05-06 2017-11-09 Taris Biomedical Llc Method of treating lower tract urothelial cancer
BR112020000832A2 (pt) * 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
IL274343B2 (en) * 2017-11-08 2023-10-01 Taris Biomedical Llc Treatment methods and maintenance treatment for bladder cancer using gemcitabine
MX2021001264A (es) 2018-08-01 2021-07-02 Taris Biomedical Llc Métodos para tratar la vejiga hiperactiva con el uso de trospio.
EP4039279A4 (en) * 2019-10-03 2023-11-01 Seikagaku Corporation TRANSMUCOSAL MEDICINAL ACTIVE DELIVERY SYSTEM FOR THE BLADDER SUBMUCOSA
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
JP2023512652A (ja) * 2020-01-27 2023-03-28 アイソラ セラピューティクス，インコーポレイテッド 管腔内局所薬剤送達のための組織内投与
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089604A2 (en) * 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
WO2012106714A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CA2520610A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
CN102176931B (zh) 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
CN104812395A (zh) * 2012-08-31 2015-07-29 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
SG10201708522SA (en) 2013-03-15 2017-12-28 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
MX391755B (es) 2013-03-15 2025-03-21 Taris Biomedical Llc Dispositivos de administración de medicamentos y métodos para administración de medicamentos.
CN113413537A (zh) 2013-08-19 2021-09-21 塔里斯生物医药公司 多单元药物递送装置和方法
WO2015069723A1 (en) * 2013-11-05 2015-05-14 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
RS67337B1 (sr) 2014-03-06 2025-11-28 Taris Biomedical Llc Sistemi za isporuku leka i metode za lečenje karcinoma bešike gemcitabinom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089604A2 (en) * 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
WO2012106714A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug

Also Published As

Publication number Publication date
EP4124339A1 (en) 2023-02-01
IL247347A0 (en) 2016-11-30
KR20160124425A (ko) 2016-10-27
AU2020217383B2 (en) 2022-09-08
JP7061595B2 (ja) 2022-04-28
HRP20251264T1 (hr) 2025-12-05
IL247347B2 (en) 2025-03-01
JP2017508749A (ja) 2017-03-30
RS63675B1 (sr) 2022-11-30
NZ723303A (en) 2023-10-27
EP4124339B1 (en) 2025-09-10
IL311410A (en) 2024-05-01
EP3113782A1 (en) 2017-01-11
SG10202101978SA (en) 2021-04-29
PT3113782T (pt) 2023-01-05
WO2015134911A1 (en) 2015-09-11
MX2016011333A (es) 2016-12-07
HUE060704T2 (hu) 2023-04-28
LT4124339T (lt) 2025-11-10
BR112016020381A8 (pt) 2018-05-02
AU2015226901B2 (en) 2020-05-14
EP3113782B1 (en) 2022-09-28
US20150250717A1 (en) 2015-09-10
US20220347091A1 (en) 2022-11-03
DK3113782T3 (da) 2022-10-17
US20220117886A1 (en) 2022-04-21
JP2019218410A (ja) 2019-12-26
SMT202500385T1 (it) 2025-11-10
JP2022022235A (ja) 2022-02-03
SG11201607342QA (en) 2016-10-28
PL4124339T3 (pl) 2025-11-17
JP7383681B2 (ja) 2023-11-20
PL3113782T3 (pl) 2023-01-23
HRP20221252T1 (hr) 2022-12-09
PT4124339T (pt) 2025-11-04
CN119950539A (zh) 2025-05-09
CA2939979A1 (en) 2015-09-11
RU2694902C1 (ru) 2019-07-18
AU2022215156A1 (en) 2022-09-01
IL247347B1 (en) 2024-11-01
SMT202200449T1 (it) 2023-01-13
AU2015226901A1 (en) 2016-09-01
CA2939979C (en) 2023-03-21
AU2024259822A1 (en) 2024-11-28
JP2024009034A (ja) 2024-01-19
CN106102751A (zh) 2016-11-09
SI4124339T1 (sl) 2025-11-28
AU2020217383A1 (en) 2020-09-03
LT3113782T (lt) 2022-11-25
ES2930435T3 (es) 2022-12-13
RS67337B1 (sr) 2025-11-28
FI4124339T3 (fi) 2025-10-17
AU2022215156B2 (en) 2024-09-05
IL311410B1 (en) 2025-07-01
JP6901858B2 (ja) 2021-07-14
BR112016020381A2 (pt) 2017-08-15
IL311410B2 (en) 2025-11-01
DK4124339T3 (da) 2025-10-13

Similar Documents

Publication Publication Date Title
KR102338079B1 (ko) 젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법
US10406335B2 (en) Drug delivery systems and methods for treatment of prostate
HK40088274A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
HK40042011A (en) Drug delivery systems and methods for treatment of prostate
NZ723303B2 (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5